[1][2][3] It is taken orally.[1] The drug is being developed by GRIN Therapeutics.[1] As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures.[1] The drug was first described in the scientific literature by 2003.[4]
See also
References
- 1 2 3 4 5 “GRIN Therapeutics”. AdisInsight. 28 December 2025. Retrieved 16 January 2026.
- ↑ Auvin S, Dozières-Puyravel B, Avbersek A, Sciberras D, Collier J, Leclercq K, et al. (March 2020). “Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome”. Annals of Clinical and Translational Neurology. 7 (3): 343–352. doi:10.1002/acn3.50998. PMC 7085998. PMID 32106360.
- ↑ Mullier B, Wolff C, Sands ZA, Ghisdal P, Muglia P, Kaminski RM, et al. (September 2017). “GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors”. Neuropharmacology. 123: 322–331. doi:10.1016/j.neuropharm.2017.05.017. PMID 28533163.
- ↑ Farkas S, Horvath C, Nagy J (2003). RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Society for Neuroscience. Washington, DC. Program No. 382.8. 2003 Abstract Viewer/Itinerary Planner.